CHIH-HSIN YANG2020-05-262020-05-2620191470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064943159&doi=10.1016%2fS1470-2045%2819%2930085-3&partnerID=40&md5=7f6c7d2d1c636489e83c0a1e3d381160https://scholars.lib.ntu.edu.tw/handle/123456789/494892[SDGs]SDG3atezolizumab; bevacizumab; dacomitinib; epidermal growth factor receptor; erlotinib; gefitinib; osimertinib; paclitaxel; bevacizumab; EGFR protein, human; epidermal growth factor receptor; erlotinib; cancer staging; EGFR gene; gene mutation; human; median survival time; non small cell lung cancer; Note; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; progression free survival; randomized controlled trial (topic); lung tumor; non small cell lung cancer; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasmsnote10.1016/S1470-2045(19)30085-3309756292-s2.0-85064943159